Hologic, Inc. (HOLX)

Market Cap	13.11B
Revenue (ttm)	4.03B
Net Income (ttm)	556.70M
Shares Out	222.85M
EPS (ttm)	2.39
PE Ratio	24.60
Forward PE	13.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,727,807
Open	58.02
Previous Close	56.75
Day's Range	57.82 - 59.02
52-Week Range	51.90 - 84.67
Beta	0.55
Analysts	Buy
Price Target	79.00 (+34.33%)
Earnings Date	May 1, 2025

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Forecast

According to 14 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $79.0, which is an increase of 34.33% from the latest price.

Price Target

$79.0

(34.33% upside)

Analyst Consensus: Buy